Prostate Cancer Research
- 8/12/2014New Cancer Classification System Might Boost Patient Outcomes | Categorizing tumors by cell type and not the organ they grow in may alter treatment, experts say
- 8/11/2014Is the PSA Test Worth It? Major Study Is Inconclusive | While the prostate screen does seem to save lives, worries about overdiagnosis remain, experts say
- 8/5/2014CAP Publishes Recommendations for Prostate Cancer Active Surveillance | Active Surveillance Provides Low-Risk Patients Less Harmful Treatment Option
- 7/14/2014Depression May Make It Harder to Beat Prostate Cancer | Men with both conditions have worse survival odds, study contends
- 7/2/2014Making Science Real: Scientists Moving Forward in Addressing Research Integrity; Learning from Past Mistakes | Poor scientific reproducibility is a product of poor reagents, sloppiness, selective publishing of data, and on occasion – outright fraud.
- 6/5/2014The Prostate Cancer Foundation Congratulates PCF Investigator Dr. Nima Sharifi on his 2014 award from the AACR for Outstanding Achievement in Cancer Research | At the 2014 AACR Annual Meeting, Prostate Cancer Foundation Investigator Dr. Nima Sharifi was honored with the 34th Annual AACR Award for Outstanding Achievement in Cancer Research
- 6/5/2014The Prostate Cancer Foundation Congratulates PCF Investigator Dr. Levi Garraway on both his AACR award—the Jane Cooke Wright Lectureship, and his Paul Marks Prize for Cancer Research from Memorial Sloan-Kettering Cancer Center | Prostate Cancer Foundation-funded Investigator Dr. Levi A. Garraway takes home two awards: The Jane Cooke Wright Lectureship Award at the 2014 AACR Annual Meeting & Memorial Sloan-Kettering Cancer Center’s Paul Marks Prize for Cancer Research
- 6/5/2014How the immune system can be harnessed to kill cancer | Understanding and improving on immunotherapies was a major focus at the 2014 AACR Annual Meeting.
- 6/3/2014New Drug May Boost Survival for Advanced Prostate Cancer Patients: Study| Enzalutamide also delays need for chemotherapy, researchers report
- 6/2/2014New Approach May Boost Survival From Advanced Prostate Cancer| Adding generic docetaxel to standard hormonal treatment seems to have benefit, study shows
- 5/29/2014Advances in Prostate Cancer Research from the 2014 AACR Annual Meeting | At the 2014 AACR Annual Meeting held in San Diego, CA this spring, Prostate Cancer Foundation-funded investigators discussed recent progress and exciting new studies regarding prostate cancer biology and treatment.
- 5/19/2014 Dogs May Help Spot Human Prostate Cancers, Study Finds | With training, 2 dogs smelled urine samples and detected tumors with nearly 100 percent accuracy
- 5/14/2014Finding Cancer Solutions, One Cell at a Time | Hot new technologies and methods are making leaps forward in studying individual cancer cells—which will help prevent drug resistance to therapy and identify new drug targets
- 4/17/2014 Quarter of Prostate Cancer Patients May Abandon 'Watchful Waiting' Approach | European study tracked how many men came back for regular checkups over 13 years
- 4/1/2014 Cialis May Not Prevent Impotence in Men Treated for Prostate Cancer | Study sees little value in taking the drug during radiation treatment
- 3/28/2014PCF researchers discover molecular crosstalk that prostate cancer cells use to survive radiation therapy; plan steps to halt that “conversation” | Prostate Cancer Foundation-funded researchers published two studies this fall that help explain why androgen deprivation therapy improves survival when given with radiation therapy
- 3/27/2014 Slight Drop in Rate of Advanced Cancers, CDC Says | Number of cases where tumors have spread beyond origins declined, but experts say more can be done
- 3/26/2014 Ask the Doctor; Calcium Supplements and Prostate Cancer Risk | Dr. Edward Giovannucci answers
- 3/6/2014 NEJM Study Finds Surgery May Benefit Younger Prostate Cancer Patients | Study adds fodder to the operate vs. 'watch and wait' debate
- 3/4/2014 Statins and Prostate Cancer | As the science comes together, risk of aggressive disease may be abated with use, but little effect on indolent, early prostate cancers
- 2/24/2014 New Drug Options in Advanced Prostate Cancer Raise Questions on Treatment order | Medscape Video Presentation
- 2/21/2014 Will Having a Biopsy Raise my PSA Level? | You asked; PCF Answers.
- 2/21/2014 Vitamin E, Selenium Supplements Might Double Chances of Prostate Cancer | Risk was highest when men had high or low levels of selenium already in their body
- 2/18/2014 "Delivering a Triple-Knockout Punch to Prostate Cancer—A novel cancer immunotherapy approach receives a $1 million Movember-Prostate Cancer Foundation Challenge Award" | Coaxing our natural immune system to fight off cancer cells in the body has been historically and frustratingly difficult
- 1/28/2014 Drug May Extend Survival for Men With Advanced Prostate Cancer | Study participants hadn't received any treatment with chemotherapy
- 1/28/2014 Improving methods to identify indolent versus aggressive prostate cancer | At the 2014 AACR - PCF Advances in Prostate Cancer Research Conference
- 1/27/2014 Exercise and Prostate Cancer—the evidence stacks up for benefits | New research adds credence for why men ought to exercise both before and after a prostate cancer diagnosis to maximize their chances of longer survival and/or improved quality of life
- 1/21/2014 Sleep hormone tied to possible lower prostate cancer risk | Preliminary study measured levels of melatonin in Icelandic men
- 1/16/2014 Patient-Centered Drug Development (video) | Doc, How will this this anti-cancer drug make me feel?
- 1/10/2014 Two-thirds of new FDA-approved drugs to treat prostate cancer driven by Prostate Cancer Foundation support | The Journal of Clinical Oncology has just published an item detailing the Prostate Cancer Foundation’s deep involvement in bringing new drugs against prostate cancer to market
- 1/10/2014 An Aspirin a Day to Keep the Prostate Cancer at Bay? | PCF Young Investigator, Dr. Jennifer R. Rider of Brigham and Women’s Hospital and the Harvard School of Public Health looks into what impact aspirin therapy might have on prostate cancer
- 1/9/2014 Geraldine Gueron, a Prostate Cancer Foundation Young Investigator, has been named by MIT Technology Review as a Top Innovator Under 35 for 2013 | The Massachusetts Institute of Technology’s Technology Review 35, or MIT TR35, award is an “annual celebration of people who are driving the next generation of technological breakthroughs.”
- 12/20/2013 Moving the Dial to Cure; Can Targeted Radiotherapy actually eradicate tumors in men with advanced prostate cancer? | Until recently radiation therapy for advanced prostate cancer was only used to alleviate pain; now it has been shown to extend life
- 12/03/2013 Your Stomach on Chemotherapy | Two new resources, developed by experts, aim to help cancer patients undergoing active cancer treatments maintain weight and boost appetites.
- 11/26/2013 Number of Circulating Tumor Cells May Predict Survival in Men with Metastatic Treatment-Resistant Prostate Cancer, May Aid Delivery of Personalized Cancer Care. | Enumeration of Circulating Tumor Cells for Clinical Decision Making
- 11/21/2013 The Prostate Cancer Foundation Unveils Major Initiative to Improve Accuracy of Laboratory Cancer Studies | Best Practices in Cell Line Authentication
- 11/15/2013 Researchers Identify Cell Type That May Be Early Inducer of Prostate Cancer | With efforts from the Prostate Cancer Foundation and the U.S. prostate cancer advocacy community, led by the Prostate Cancer Roundtable, the 2012 budget for Congressionally Directed Medical Research Programs was preserved
- 11/12/2013 21st Century Medicine—Synthetically Engineered Cancer Biomarkers (video) | At this year’s Prostate Cancer Foundation’s 20th annual scientific retreat, attendees were dazzled by research out of MIT that uses nanoparticles for early cancer detection and monitoring as well as sussing out tiny blood clots in the body
- 11/08/2013 Cancer Patients Taking Statins May Have Lower Risk of Dying | Cancer patients may lower their risk of dying from the disease if they take the cholesterol-lowering drugs called statins, a new study from Denmark suggests
- 11/04/2013Teaching an Old Drug New Tricks to Fight Prostate Cancer | Their novel drug candidates kill tumor cells by activating an enzyme that turns off key cancer-promoting proteins
- 10/30/2013 Promising Nanomedicine Advances to Phase II Clinical Trials | Docetaxel has long been used to treat advanced forms of prostate cancer; now an ingenious targeted drug platform will deliver this chemotherapeutic directly to tumors, allowing higher dosing with fewer side effects
- 10/24/2013 Cool Technology: Stretchy Electronics and Sensors that Can Dissolve in Your Body | A 21st century interface of engineering and oncology may bring better medicine to patients. Learn about electoceuticals and how they may help prevent infections, and why next-generation electronics that can stretch to fit over catheters or dissolve once no longer needed may benefit patients
- 9/26/2013 Stress May Dampen Response to Anti-Cancer Therapies | Heightened stress levels have been shown to have deleterious effects on patients with multiple sclerosis, increase the risk of dementia in the aged, and speed up cellular DNA aging
- 9/25/2013 New Urine Test for Prostate Cancer Available; Unlike PSA Test, is Ultra-Specific for Prostate Cancer | A new urine test for prostate cancer is now available
- 9/25/2013Building a Better Mousetrap to catch Prostate Cancer | New urine test for prostate cancer improves utility of the PSA blood test, increases doctors’ ability to pick out high-risk tumors from low-risk tumors in patients, and may help tens of thousands of men avoid unnecessary biopsies
- 8/23/2013 Letters from Bozeman – Kenneth May, Jr., MD, PhD; Second in a Series: Postcard from the Cutting Edge: ASCO in Chicago | Dr. May travels to the Heartland for a major cancer conference, and returns home to Montana with valuable information that enables one of his patients to gain insurance approval for a newly FDA-approved prostate cancer drug
- 7/24/2013 Subtype of Highly Aggressive Prostate Cancer Increasing; Tied to Drug Resistance to Hormone Therapy | Novel drug being tested in multi-site Phase II clinical trial to treat men with this aggressive form of prostate cancer known as neuroendocrine prostate cancer
- 7/24/2013 Xofigo Results Published in New England Journal of Medicine – Explanatory Video Accompanies Publication | The Prostate Cancer Foundation has repeatedly reported on this drug’s development and movement to market
- 7/02/2013 Breakthrough in Nano-Medicine Chemotherapy Drug Delivery in Phase II Trials | Think of this nanoparticle technology as a Chemotherapy ExpressLine Bus Service
- 6/24/2013 With FDA-Approval of Xofigo, Many Men with Advanced Prostate Cancer Can Expect Improved Quality of Life | Listen as Doctors Discuss Xofigo in greater detail
- 6/20/2013 A New Diet to Quash Inflammation May Benefit Men's Prostate Health | The anti-inflammatory diet is trending; could it help prevent prostate cancer or enhance survivorship? Recent evidence suggests: yes
- 6/10/2013 Prolaris Prostate Cancer Test Highly Predictive of Tumor Lethality | Summary Results of five studies of test presented at this year’s ASCO meeting in Chicago
- 6/04/2013 Personalizing Cancer Care: PARP Inhibitor + Hormone Therapy for Advanced Prostate Cancer | Study to determine if prostate cancer patients with prevalent gene-fusion mutation benefit from addition of PARP inhibitors to Hormone Therapy
- 5/23/2013 New genetic test to diagnose highly lethal form of prostate cancer enters commercial development; may lead to increased survival | The occurrence of a rare and highly aggressive form of prostate cancer known as neuroendocrine prostate cancer (NEPC) is increasing
- 5/20/2013 A Layman's Guide to Prostate Cancer Genes | Prostate Cancer Genes Begin to Tell Their Story
- 5/15/2013 Another new drug (Xofigo (radium-223) that extends survival time for men with advanced prostate cancer gains FDA approval | Xofigo (radium-223) is the second prostate cancer drug to treat metastatic disease that has come to market during the past year; the first bone-targeted drug to improve survival
- 5/13/2013 Taking the Lethal out of Prostate Cancer; Plus, Entirely New Class of Drug Shows Promise Against Advanced Disease (video) | Entirely New Class of Drug Shows Promise Against Advanced Prostate Cancer
- 5/8/2013 New Test Can Better Tell Need For Surgery vs. Active Surveillance | Prostate Cancer Foundation funded early research that underpinned test’s development.
- 5/08/2013 New 17-gene test enhances ability to predict aggressiveness of prostate cancer; may spare men unnecessary surgery/radiation | Prostate Cancer Foundation funded early research that underpinned test’s development
- 5/02/2013 Statins May Reduce Prostate Cancer Deaths | The role of statins in mitigating prostate cancer risks has been debated often during the past few years
- 4/26/2013 Can Botox Tame Prostate Cancer? | Botox shriveled tumor cells in men prior to surgery; injections of the drug into tumor may enhance effects of radiation therapy
- 4/25/2013 Zytiga is Most Used First-Line Treatment for Stage IV Prostate Cancer | Market data released this week shows the new drug’s share of the first-line prostate cancer market has steadily increased to 30 percent since its launch in 2011
- 4/22/2013 News Roundup—prostate cancer news makes headlines at the annual meeting of the American Association for Cancer Research | Selenium-Prostate Cancer Link Again Under Debate
- 4/22/2013 Cancer Centers Race to Map Patient’s Genes | Researchers now acknowledge that studying the few ‘exceptional responders’ in failed clinical trials can yield new insights into cancer
- 4/19/2013 Cancer Researchers Revisit 'Failed' Clinical Trials and Begin Study of the One to Ten Percent of Patients Who Responded to Treatment | The ability to map the genes of cancer patients and determine the specific genotype (variety) of their tumors is rapidly moving
- 4/15/2013 Prostate Cancer Foundation Young Investigators Advance Cancer Research at the 2013 AACR in Washington | This year, AACR presentations related to prostate cancer were chock full of Prostate Cancer Foundation Young Investigators
- 4/8/2013 Rally For Medical Research | The Prostate Cancer Foundation (PCF) is one of over 200 partnering organizations supporting this important event.
- 4/5/2013 Third-Generation Device Significantly Improves Capture of Circulating Tumor Cells | A new system for isolating rare circulating tumor cells (CTCs) -- living solid tumor cells found at low levels in the bloodstream -- shows significant improvement over previously developed devices and does not require prior identification of tumor-specific target molecules
- 4/5/2013 Study Changes the Way Doctors Practice | A new study shows that continuous hormone therapy (androgen deprivation therapy) helps men more than intermittent or pulsed hormone therapy.
- 4/5/2013 The Link Between Early Baldness and Prostate Cancer | Researchers have long known about the potential link between baldness and the risk of prostate cancer, but studies have been conflicting
- 4/3/2013 A Year After Common, Novel SPOP Prostate Cancer Gene Mutation Identified, Researchers Determine Its Route to Cancer | When SPOP is mutated it no longer can act as a tumor suppressor gene
- 3/29/2013 DNA Test Reveals 80 Markers for Inherited Breast, Prostate and Ovarian Cancer Risks | News continues to come out of research labs about new diagnostic markers for predicting and diagnosing cancer with more assurance
- 3/27/2013 New Diagnostic Tests in the Pipeline for Prostate Cancer | Recent advances in research have improved our understanding of prostate cancer, which is beginning to be appreciated more as a collection of different subtypes instead of a single uniform disease
- 3/13/2013 Delivering on the Promise to Young Scientists | The young do not know enough to be prudent
- 3/12/2013 Mushroom and Soybean Extract May Boost Effectiveness of Androgen Deprivation Therapy | GCP, or genistein-combined poloysaccharide—found in shiitake mushrooms and soybeans and produced as a proprietary extract
- 3/12/2013 Women’s History Month and Women in Science | Women in Science—gains and remains
- 3/12/2013 April Rally for NIH Funding set for DC | The Rally continues work begun 20 years ago, leading to the first-ever Cancer Summit in 1995 and the 1998 MARCH on Washington
- 3/8/2013 Androgen Deprivation Therapy Increases Risk for Gallbladder Disease | Because male hormones, or androgens such as testosterone, fuel prostate cancer growth androgen deprivation therapy (ADT) is a mainstay in the treatment for certain forms of prostate cancer and has been proven to improve survival times
- 3/8/2013 Markers May Indicate Occult High-Grade Prostate Cancer | Epigenetic changes in benign tissue sampled during prostate biopsy confirmed as "field effect" biomarkers of undetected tumor
- 3/1/2013 American Society of Clinical Oncology Genitourinary Cancers Symposium Report - Advances March 2013 Issue | Highlights of This Year’s Meeting
- 2/26/2013 Anticoagulant Use During Chemotherapy and Prostate Cancer Survival Rates | The study retrospectively reviewed the medical charts of 247 men with metastatic, treatment resistant prostate cancer
- 2/26/2013 SNPs and Prostate Cancer and Radiation Therapy | PCF-funded researchers led by Dr. Lorelei Mucci presented data at the 2013 Genitourinary Cancers Symposium in Florida
- 2/22/2013 High-Fiber Intake in Mice Shrinks Prostate Tumors | Researchers have long believed that native Chinese and Japanese men who consume diets high in fiber have very low rates of prostate cancer progression
- 2/21/2013 Role of Radical Prostatectomy in Patients With Prostate Cancer | Even in the presence of screening, there is benefit to radical prostatectomy (RP) in prostate cancer patients
- 2/11/2013 More Data Links Prostate Cancer With Dairy Consumption | Prior studies have shown that higher overall milk intake is associated with a greater risk of developing prostate cancer
- 2/11/2013 CTC Technology Advances Prostate Cancer Diagnostics | The Prostate Cancer Foundation has invested more than $3 million in the past five years to advance CTC technology at several research centers
- 2/8/2013 Redux REDUCE-Chemoprevention for Prostate Cancer Remains Controversial | New Study Finds No Increased Risk of High-Grade Prostate Tumors in Men Taking Dutasteride; However, Study Unlikely to Sway Detractors of Using the Drug as a Chemoprevention Agent
- 2/6/2013 African American History Month | Health Gains and Health Disparities in the African American Community
- 2/1/2013 PCF-Funded Investigator to Lead New Institute for Precision Medicine | Precision medicine is the ultimate goal in treating prostate cancer so we can cure more and overtreat less
- 1/31/2013 NEJM Study on Long-Term Side Effect Functional Outcomes After Treatment for Localized Prostate Cancer | At two years post diagnosis, men who had surgery were about six times more likely to have urinary incontinence compared to men who received radiotherapy
- 1/29/2013 Study Validates Unfavorable Role of Fried Food in Prostate Cancer | Fried foods are practically an American staple—from fried chicken, doughnuts and French fries—these items are readily available at most corner restaurants and fast-food locations
- 1/25/2013 New Y Chromosome Research Yields Insight Into Prostate Cancer Development | A large international 10-year project launched last year, titled the Human Proteome Project, ambitiously aims to map all proteins produced by genes on human chromosomes
- 1/24/2013Cost-Effectiveness Study Compares Surgery and Radiation Therapy for Localized Prostate Cancer—Small Differences in Outcomes, Big Differences in Cost | Dr. Cooperberg explains that they ran and reran the men through their various treatment algorithms and that a certain number of men would wind up in each possible health state
- 1/24/2013 Study Brings Science One Step Closer to a Completed Cityscape Map of Epigenetic Changes That Drive Metastatic Prostate Cancer | Now a new study in Science Translational Medicine that analyzed the whole genomes of 13 men who had expired from metastatic prostate cancer finds epigenetic changes that were consistent and stable in individual patients
- 1/23/2013 Androgen Receptor Pathway Agents Continuing to Change the Landscape of Prostate Cancer | For men diagnosed with prostate cancer, treatment options of many forms are readily available for use
- 1/22/2013 Investigational Agent Orteronel (TAK700) Holds Promise in the Post-Abiraterone, Post-Enzalutamide Era | The past year has been exciting for prostate cancer patients with newer, more potent agents such as abiraterone and enzalutamide being added to the prostate cancer treatment armamentarium
- 1/18/2013 PSA Pros and Cons Not Always Discussed Between Doctor and Patient | The prostate specific-antigen (PSA) test is a simple blood test that detects possible problems within the prostate gland, including the potential of infection and sometimes, cancer
- 1/17/2013 Focal Therapy for Prostate Cancer Explained in Research Review | Researchers from Duke University Medical Center studied the evolution of focal therapy as a reasonable option for men with clinically localized, low-grade disease
- 1/15/2013 Kaiser Permanente Study Finds Changes in Prostate Specific Antigen Levels over Time can Help Predict Aggressive Prostate Cancer | Measurements taken over time of prostate specific antigen, the most commonly used screening test for prostate cancer in men
- 1/14/2013 Mapping PCa’s Genetic Landscape Just Got a Bit Easier and Potentially Less Expensive | Cancer genetics researchers study tumors for clues; they want to know how the tumor got there in the first place
- 1/11/2013 Johnson Gets Expanded Approval for Zytiga Cancer Treatment in EU | Johnson & Johnson's (JNJ) Janssen-Cilag International NV said it has received approval from the European Commission that allows its cancer treatment Zytiga to be adopted in the European Union earlier in the treatment process
- 1/9/2013 PCF Honors the Late General H. Norman Schwarzkopf | As the General learned more about his new "enemy," he was led to Milken and the Prostate Cancer Foundation
- 1/9/2013 Saying He's 'Finished' With Prostate Cancer Treatment, Gov. Jerry Brown Pronounces Himself 'Rarin' to Go' | Gov. Jerry Brown said Tuesday he's "finished" with his treatments for prostate cancer and pronounced himself fit for the rough haul ahead, which includes rolling out the state budget Thursday
- 1/9/2013 Study Finds Active Surveillance Safe and Effective for Monitoring Low-Risk Prostate Cancer Patients; Recommends Restaging Biopsy Prior to Enrollment | Active Surveillance is a monitoring program employed for patients diagnosed with low-risk prostate cancer
- 1/8/2013 New Center for Prostate Cancer to be led by PCF Researcher Dr. Ashutosh Tewari | Researcher, mentor and long-time friend to PCF, Dr. Ashutosh Tewari will lead the new Center for Prostate Cancer at New York-Presbyterian/Weill Cornell Medical Center
- 1/4/2013 The Partin Tables Used to Predict Cancer Stage at Prostatectomy Updated | The information is used to assist men diagnosed with prostate cancer and their doctors assess the chance of a surgical cure
- 12/21/2012 Prostate Cancer: What Did We Learn From the 2012 Annual Scientific Meeting of ASCO? | In recent years, management of prostate cancer has benefited from an expanding array of new pharmacological options
- 12/20/2012 Epigenetics and Cancer | An Enzyme’s Functional Switch May Fuel Treatment-Resistant Prostate Cancer; Drug Target More Clearly Limned
- 12/19/2012 New England Journal of Medicine Publishes Positive Phase III Clinical Results for Zytiga (abiraterone) in Men Without Prior Chemotherapy—Should Bolster Medical Reimbursements | The study was a multinational, double-blind, randomized evaluation of 1,088 men assigned to receive either Zytiga and prednisone, or placebo plus prednisone
- 12/18/2012 California a Leading State for Research Into Cancer Afflicting Gov. Brown | Newly diagnosed with prostate cancer, Gov. Jerry Brown governs one of the leading states in the country in terms of research into the disease
- 12/17/2012 First Patient Inducted into Phase II Clinical Trial Evaluating Galeterone | Building on the success of Phase I clinical trials, Tokai Pharmaceuticals has advanced its lead prostate cancer drug for the treatment of advanced disease into Phase II trials this week.
- 12/17/2012 New Research Aims To Make Cancer Drugs With 3D Printers | Over the last year, 3D printers have inspired a lot of futuristic ideas. One of the more lofty ideas was the creation of medicine via 3D printing
- 12/13/2012 Phase II Clinical Trial for Galeterone Begins Treating First Patient | The Phase II, ARMOR2 trial will evaluate galeterone in 196 patients, who are either treatment-naïve, or those whose disease has progressed despite therapy with Zytiga (abiraterone acetate)
- 12/12/2012 MRI-Ultrasound Fusion Technology Targets Prostate Biopsies | One of the biggest challenges of prostate cancer is the diagnostic process, with respect to both finding tumors within the prostate and obtaining the most precious biopsy samples
- 12/11/2012 Childhood Leukemia Researcher Makes Headlines, Now Works toward Prostate Cancer | One of the biggest challenges of prostate cancer is the diagnostic process, with respect to both finding tumors within the prostate and obtaining the most precious biopsy samples
- 12/11/2012 Promising Phase III Clinical Trial Successfully Enrolls 1,200 Patients | Tasquinimod, or TASQ, is an oral experimental treatment for men with metastatic treatment resistant prostate cancer
- 12/10/2012 J&J’s Zytiga Wins Approval for Earlier Use in Prostate Cancer | Johnson & Johnson won approval for its prostate cancer pill Zytiga to be used earlier in the disease, possibly spurring four times as many patients to take the medicine
- 12/07/2012 Common Bacteria Examined in Prostatectomy Samples | In this preclinical study, the researchers found that their novel drug was indeed activated by PSA in prostate cancer cells and lead to P13K inhibition and cancer cell death
- 12/04/2012 Promising Results for 1st Prostate Cancer-Targeted Prodrug Against Signaling Pathway (PI3K) Associated with Substantial Number of Prostate Tumors | In this preclinical study, the researchers found that their novel drug was indeed activated by PSA in prostate cancer cells and lead to P13K inhibition and cancer cell death
- 12/03/2012 PET Scans to Image Prostate Cancer Advance Toward Mainstream Clinical Use | This project was partially supported by a PCF Creativity Award made possible through generous support of Movember
- 11/29/2012 The Microfluidic VerIFAST | On October 26, 2012, PCF-funded Young Investigator Joshua Lang, MD presented data on the VerIFAST platform and the development of circulating tumor cell isolation and staining technology.
- 11/29/2012 Vitamin D Mechanism of Action Discovered by McGill University | Vitamin D has long been believed to play an important role in prostate and other cancers, though its mechanism of action had yet to be verified.
- 11/26/2012 Epigenetics and Prostate Cancer – New Findings May be of Particular Importance for Men Lacking a Common Genetic Fusion Abnormality | Determining what drives prostate cancer development and progression is the key to finding ways to alter than course and prevent deaths from this disease.
- 11/16/2012 Glutamate, an Agent in Cancer Metabolism, Identified as a Biomarker for Prostate Cancer | There is a critical unmet medical need to identify disease biomarkers that can efficiently report on the underlying biology of an individual patient’s cancer.
- 11/16/2012 Non-Invasive, Biodegradable Brachytherapy Treatment Makes Headlines | Brachytherapy is a common treatment used for prostate cancer patients.
- 11/16/2012 Prostate Cancer Antibody Attacks Metastatic, Treatment-Resistant Disease | Daniel Petrylak, MD, of Yale University Medical Center and a past PCF-funded investigator, led a research study evaluating an antibody-drug that targets prostate-specific membrane antigen (PSMA)
- 11/16/2012 Recurrent Prostate Cancer May Be Explained Through Deeper Understanding of Androgen Receptor | Androgens are male hormones that fuel the growth and spread of prostate cancer.
- 11/16/2012 Bar Code Tests Spot Aggressive Prostate Cancers | Aside from curing prostate cancer, the holy grail of this disease is to determine which cancers require aggressive treatments
- 11/08/2012 Cancer Patients Taking Statins May Have Lower Risk of Dying | Cancer patients may lower their risk if they take the cholesterol-lowering drugs called statins
- 11/08/2012 New Targeted Therapy for Advanced Prostate Cancer Shows Anti-tumor Activity in Clinical Trials | Few available treatment options exist once prostate cancer has spread to other parts of the body and has failed to respond to therapies that involve blocking the male hormone androgen.
- 11/01/2012 Memorial Sloan-Kettering Researchers Discover Prostate Cancer Disease Pathways Regulate Each Other | Researchers discover a specific combination of inhibitors which cause tumor recession in mouse models.
- 11/01/2012 Ultra-sensitive Sensor Developed to Detect both HIV and Prostate Cancer at Earlier Stage | Treatments for diseases like HIV infection and prostate cancer have made considerable progress in the past decades.
- 10/29/2012 Online Prostate Cancer Database Launched to Help Patients decide Whether to Risk Aggressive Treatment | Men diagnosed with slow-growing, non-life threatening prostate cancer can now track the progression of their disease online.
- 10/26/2012 Stat5 Predicts Early Disease Recurrence and Prostate Cancer Specific Deaths in Patients After Radical Prostatectomy | There is an urgent unmet medical need to identify robust markers to identify patients whose prostate cancer will recur after initial treatment and progress to aggressive disease.
- 10/26/2012 Mystery of Trop2 Protein Unveiled | The proteinTrop2 has long been considered a vital component to understand disease progression in several cancers.
- 10/22/2012 BMI, BP Don't Up Prostate Cancer Risk | Metabolic factors did not increase the risk of prostate cancer but modestly raised the risk of prostate cancer mortality.
- 10/16/2012 Bar Code Tests Spot Aggressive Prostate Cancers | Aside from curing prostate cancer, the holy grail of this disease is to determine which cancers require aggressive treatments.
- 10/9/2012 A Nine-gene Signature Identified for Aggressive Prostate Cancers | David Olmos, Johann de Bono, first and senior authors respectively, Lancet Oct 2012—Study funded in part by PCF
- 10/5/2012 New Data Shows Added Benefits for Prostate Cancer Drug Enzalutamide | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/5/2012 Novel Anti-androgen Drug Shows Potential Anticancer Effects in 87% of Men with Advanced Form of Prostate Cancer in Early Clinical Testing | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/4/2012 Common Drug Used to Treat Diabetes May Benefit Subset of Prostate Cancer Patients | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/4/2012 Novel Anti-Sense Drug Lowers PSA Levels and Delays Disease Progression in a Phase II Clinical Trial | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/2/2012 Protein Found in Prostate Cancer May Promote Cancer Growth and Progression | The protein PARP1 is known to play a crucial role in DNA repair.
- 10/2/2012 Novel Radiopharmaceutical Shows Survival and Quality of Life Benefit to Men with Metastatic PCa | From this year’s European Society for Medical Oncology (ESMO) Congress in Vienna September 28-October 2, 2012
- 10/1/2012 Men Have More Options in Prostate Cancer Treatments | Jim Kiefert of Olympia, Wash., has been battling prostate cancer for 23 years. The retired school administrator, 74, has never been more optimistic about his prospects than he is now.
- 10/1/2012 The War on Cancer Reboots | It's been a fight that has been going on for four decades, but new technologies are allowing us to get a better understanding of how cancers work, reports Alex Philippidis in Streetwise's Life Sciences Report.
- 9/26/2012 Published Study Finds Little Benefit in Prostatectomy vs. Active Surveillance | Using the leading active surveillance cohort of prostate cancer patients at Johns Hopkins University and computational disease modeling, scientists compared prostate cancer-specific deaths in patients under active surveillance versus those that went for immediate treatment post-diagnosis.
- 9/26/2012 MD Anderson Cancer Center Initiates “Moon Shot” Program to Increase Patient Survival over Coming Decade | According to MD Anderson president Ronald DePinho, the institution has "tens of millions of dollars" to get started and plans to spend up to $3 billion over the next 10 years.
- 9/25/2012 Powerful Chemotherapy For Prostate Cancer Treatment's Underlying Mechanism Revealed | Study Suggests Role of Taxane-Based Chemotherapy Drugs May Be Underestimated and Should Be Re-examined to Improve the Drug's Effectiveness
- 9/19/2012 How We Can Pick Up The Pace In The Race To Cure Cancer | Like most men, I was totally uninformed and unprepared for what I was about to face when I received my diagnosis
- 9/19/2012 Multi Gene Predictive Signature to Discriminate Aggressive from Indolent Prostate Cancer May Allow Men to Avoid Unnecessary Treatments | Doctors know that the majority prostate cancers are slow-growing and non-lethal, but pinpointing exactly which cancers fall into this category has been historically difficult.
- 9/19/2012 Prostate Cancer Discriminates: Understanding the Unique and Urgent Needs of Black Men | Most men are totally uninformed and unprepared for what they are about to face when they received my diagnosis.
- 9/13/2012 Medivation and Astellas Announce XTANDI (Enzalutamide) Is Now Available for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel | XTANDI was approved by the U.S. Food and Drug Administration (FDA) on August 31, 2012. XTANDI is being distributed through a network of specialty pharmacies and specialty distributors.
- 9/13/2012 FDA Green-Lights PET Agent for Recurrent Prostate Cancer Detection | The FDA has approved the production and use of Choline C 11 Injection, a PET imaging agent used to help detect recurrent prostate cancer.
- 9/10/2012 Androgen-Blocking Drug Wins Approval for Prostate Cancer | Men with advanced prostate cancer now have another treatment option, thanks to the approval August 31 by the U.S. Food and Drug Administration (FDA) of a pill that blocks androgen-receptor signaling and prolongs patient survival.
- 8/30/2012 Prostate Cancer Drug Zytiga Receives Priority Review by FDA | Zytiga represents a new class of medication that suppresses testosterone in a new way, lowering testosterone levels far below the levels achieved with current androgen suppressive medications.
- 8/30/2012 Prostate Cancer Gene May Determine Tumor Growth, Return | Scientists may have found a clue to one of the most vexing questions in cancer care
- 8/29/2012 Aspirin May Aid Cancer Recovery | Men treated for prostate cancer who took aspirin regularly for other medical conditions were less likely to die of their cancer than patients who weren’t taking aspirin
- 8/23/2012 New Tools Will Aid Doctor-Patient Discussions on Prostate Cancer, Treatment Options | The recommendation was in response to evidence that indicated the harms of the test outweigh its benefits.
- 8/22/2012 Nanotechnology in Personalized Medicine | Introduction to nanomedicine
- 8/17/2012 Enzalutamide Prolongs Survival in Treatment-resistant Prostate Cancer Patients | Androgen (male hormone) signaling remains a major driver of prostate cancer growth and spread, its activity mediated by the Androgen Receptor (AR).
- 8/16/2012 Exercise Improves Cancer Patient Lifestyle | Two separate reviews have found exercise may improve cancer patients' quality-of life, a U.S. researcher said.
- 8/16/2012 Mutation Rate in Prostate Cancer Influenced by DNA Arrangement | Cancer is a genetic disease and most of these genetic abnormalities stem from mutations in the underlying genes
- 8/16/2012 Gene Rearrangements in Pre-Cancerous Cells May Help Detect Aggressive Disease | A recent study presents a potentially valuable tool in managing prostate cancer populations: measuring rearrangements in the gene ERG in initial biopsy specimens.
- 8/14/2012 Experimental Theranostic Nanoplexes for Prostate Cancer Therapy | Imaging techniques have become a hot research concentration in the field of diagnostics, especially in prostate cancer.
- 8/13/2012 Prostate Cancer Drug Abiraterone Approved by Scottish Medicines Consortium | A drug which can extend the lives of men with incurable prostate cancer has been approved for use in Scotland.
- 8/10/2012 PCF-Funded Young Investigator Awarded by University for Exemplary Research Progress Made in Prostate | 2010 LeFrak Family PCF Young Investigator Dr. Himisha Beltran, assistant professor of medicine at Weill Cornell Medical College, was honored by the institution with The 21st Annual Department of Medicine Investigator Award.
- 8/9/2012 Prostate Cancer Microenvironment: New Targets for Cancer Control | Prostate cancer patients who undergo chemotherapy have a high probability of developing treatment resistance.
- 8/8/2012 Researchers Call for Digital Rectal Exam Revival | Rates of digital rectal examination (DRE) are low in clinical practice and levels of sufficient training in the technique may be in decline, the results of a US study suggest.
- 8/8/2012 Study Questions Value of Calcium and Vitamin D Supplements for Certain Men with Prostate Cancer | Prescribing calcium and vitamin D supplements for men at risk of bone loss from hormonal treatment for prostate cancer seems like good medicine.
- 8/6/2012 Edinburgh Study Pinpoints Prostate Cancer 'Growth' Gene | Scientists from Edinburgh University have pinpointed a gene they say could lead to improvements in the diagnosis and treatment of prostate cancer.
- 8/3/2012 Recent Stanford University Graduate Discusses Links between Infection and Prostate Cancer | According to the American Cancer Society, 20 percent of all cancers are triggered by infections
- 8/1/2012 Prostate Cancer Drug, Abiraterone, Approved for NHS Use in Northern Ireland | A "breakthrough" drug which can prolong the lives of men with terminal prostate cancer is to be made available to NHS patients in Northern Ireland.
- 8/1/2012 Study: PSA Screening for PCa and Risk of Overt Metastatic Disease at Presentation | The upshot of PSA screening demonstrated in new study
- 7/30/2012 Abandoning PSA Screening Could Cost Lives: Study | Testing could save 17,000 men from advanced prostate cancer, researcher says
- 7/25/2012 Phase III Clinical Trial Opens In Republic of South Africa, Enrolls First Patient | The first prostate cancer patient enrolled in a Phase III clinical trial and began receiving treatment on the investigational therapeutic agent Debio 8206.
- 7/25/2012 Protein Brings New Light to Understanding Prostate Cancer | The holy grail of prostate cancer is to figure out why cells stop responding to hormone therapy.
- 7/24/2012 MDV3100 (Enzalutamide) Granted Priority Review Designation by the FDA | MDV3100 is a therapeutic agent for men with advanced prostate cancer who have failed both hormone and chemo therapies.
- 7/18/2012 Landmark Study Comparing Surgical Intervention to Watchful Waiting in Men With Low Risk Prostate Cancer Shows Certain Men May Safely Forgo Surgery | The study shows that a subset of men who are properly selected can safely choose either active surveillance or a watchful waiting management approach of their diagnosed prostate cancers
- 7/16/2012 New Cancer Biomodule Regulating Prostate Cancer Initiation and Progression Identified | Proteins in the Hox regulatory network identified as potential tumor suppressors in prostate cancer initiation and progression.
- 7/6/2012 TMPRSS2-ERG and Prostate Cancer Outcomes after Prostatectomy | New study shows common prostate cancer mutation does not strongly predict disease recurrence or mortality among men treated with radical prostatectomy
- 7/2/2012 Prostate Surgery Tied to Need for Bladder Surgery | One in 20 men who have their prostate gland removed may need a second surgery for severe loss of bladder control, new research from Canada suggests
- 6/28/2012 Side Effects Persist After Prostate Cancer Treatment | Men who are treated for prostate cancer may still suffer side effects from treatment up to a decade later, a new study finds.
- 6/27/2012 Astellas and Medivation Announce European Regulatory Submission | The treatment is currently awaiting approval from the Food and Drug Administration (FDA) in the United States.
- 6/26/2012 Diagnostic Blood Test for Prostate Cancer Receives FDA Approval | A new test has been approved by the FDA that improves on the ability of PSA to detect clinically relevant and potentially lethal prostate cancer.
- 6/20/2012 Major Advancements Being Made Against Prostate Cancer, says FDA Cancer Drug Chief | For many cancer patients, treatment options remained in a holding pattern for far too long.
- 6/20/2012 A Protein Unique to Prostate Cancer Has Been Identified | Protein may be used as a biomarker to distinguish indolent from lethal disease and serve as a novel drug target
- 6/20/2012 Prostate Cancer Cell Line Study Shows Potential New Route to Cancer Progression--SLC45A3-ELK4 Fusion | A study published in Cancer Discovery has identified an unusual pathway to prostate cancer progression.
- 6/19/2012 Zytiga Approved in Australia and Singapore | Zytiga has been approved by the Health Sciences Authority of Singapore for use in treating advanced prostate cancer.
- 6/18/2012 Prostate Cancer Drug Zytiga Seeks Extended Label in U.S. and Europe | Zytiga is currently approved in combination with prednisone for men who have received prior docetaxel-based chemotherapy.
- 6/12/2012 Investigational Drug Nears FDA Approval | In early June, researchers presented data on the investigational drug during the American Association of Cancer Research (AACR) annual meeting.
- 6/5/2012 Denosumab Prolonging Bone-Metastasis Free Survival Featured at ASCO | The research team found that patients with shortened PSADT are at higher risk of developing bone metastasis, and denosumab is markedly effective at prolonging BMFS in the study’s selected subset of patients.
- 6/5/2012 Radium-223 dichloride Proves Promising in Metastatic Prostate Cancer | The ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer) trial used Radium-223 in treatment-resistant, metastatic prostate cancer patients and bone metastases.
- 6/5/2012 Investigational Drug OGX-247 Shows Patient Benefit in Phase II Clinical Trials | "We are encouraged by these early data that further support the ability of OGX-427 to suppress androgen receptor activity and tumor cell survival"
- 6/5/2012 RNA Prognostic Model Predicts Survival for Men with Prostate Cancer | Results found that the six-gene model suggests possible dysregulation in the system, which researchers believe requires further study.
- 6/5/2012 PCF-Funded Researchers Present on Cabozantinib (XL184) Data Results at ASCO Conference | While most chemotherapy is administered intravenously, Cabozantinib (XL184), is a small molecule tyrosine kinase inhibitor (TKI) that can be taken orally.
- 6/4/2012 Moving Research and Management Forward For Men with Treatment-Resistant Metastatic Prostate Cancer | So, what’s next? Presenters posed the question of what optimal sequences or therapies exist for men with treatment-resistant, metastatic prostate cancer?
- 6/4/2012 Phase I Clinical Trial Reveals Positive Immune Response in Cancers, Including Prostate | The Phase I clinical trial was conducted at five centers throughout the United States.
- 6/4/2012 Phase III Trial Results for Circulating Tumor Cell Counts and Overall Survival | Though researchers understand that CTC’s are promising biomarkers in treatment-resistant, metastatic prostate cancer, it has not been validated for docetaxel treatment.
- 6/4/2012 Cancer Antigen MICA Plays Vital Role in Immune Surveillance | Immunotherapy research remains as a promising modality for the treatment of cancer, including prostate cancer—as well as an important tool in clarifying the mechanism of action for guiding patient selection.
- 6/4/2012 Phase III Study of Abiraterone Acetate in Metastatic Disease Presented at ASCO | Results from a Phase III clinical trial were presented at the annual American Society of Clinical Oncology (ASCO) meeting today.
- 6/3/2012 Practice Changing Data Results from 17 Year Study Presented at ASCO | Investigational researcher Maha Hussain, MD, FACP of the University of Michigan Comprehensive Cancer Center presented pivotal research at the 12th annual American Society of Clinical Oncology (ASCO) meeting.
- 6/3/2012 Funding from PCCTC Advances Study of Ketoconazole and Docetaxel Response Following Abiraterone Acetate | Ketoconazole (keto) is drug used in prostate cancer to block the release of testosterone from the adrenal glands, typically administered in conjunction with steroids to avoid side effects.
- 6/3/2012 PROSTVAC Vaccine for Prostate Cancer to Enter Phase III Clinical Trials | PROSTVAC, a virus-based vaccine, successful showed an average 8.5 month overall survival benefit and favorable side effects in Phase II clinical trials
- 6/3/2012 Liver Metastases Help Predict Overall Survival in Metastatic Prostate Cancer Patients | A collaborative research team studied liver metastases in relation to overall survival in men with treatment-resistant metastatic prostate cancer (TRMPCa).
- 6/3/2012 PSA Decline Found in Phase I Clinical Trial Using KX2-391, Funding from PCCTC | The drug is potent against a broad range of solid tumor cell types, as well as many leukemia types, including those resistant to imatinib and/or dasatinib.
- 6/3/2012 Phase III Clinical Trial Compares Efficacy of Ipilimumab in Metastatic Prostate Cancer Patients | Ipilimumab is a fully human monoclonal antibody that augments antitumor response and is also responsible for blocking CTLA-4 (a protein that plays an important regulatory role in the immune system).
- 6/2/2012 Laying the Foundation For a Cure | As drug treatments for prostate cancer dominate the news at ASCO, we look back at how abiraterone (Zytiga) made its way onto the A list.
- 6/2/2012 Team of PCF-Funded Researchers Present MDV3100 Trial Results at ASCO | The clinical advancement of MDV3100 is one of the most important events in the history of prostate cancer research and the Prostate Cancer Foundation
- 6/2/2012 UCSF Reports on Abiraterone Clinical Trial, PCF-Funding Leads Innovative Research Team | Lead author Charles J. Ryan, MD, at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco and his research team presented interim data results from a Phase III clinical trial on abiraterone acetate in metastatic, chemo resistant prostate cancer patients.
- 6/2/2012 Testosterone Levels Studied in Neoadjuvant Trial | A team of prostate cancer researchers presented data during the annual ASCO conference on neoadjuvant (administration of therapeutic agents before a main treatment) androgen pathway suppression prior to prostatectomy.
- 6/1/2012 Prostate and Breast Cancer Incidences to Increase Substantially by 2030, According to Study | The worldwide incidence of cancer is expected to increase 75 percent by 2030, with a projected increase of more than 90 percent in the poorest nations, a new study reveals.
- 6/1/2012 MDV3100 Expanded Access Program for Use in Metastatic Prostate Cancer Patients | Medivation and Astellas, the manufactures of MDV3100, applied for a New Drug Application with the FDA in early May 2012.
- 5/31/2013 Funding from PCCTC Advances Study of Ketoconazole and Docetaxel Response Following Abiraterone Acetate | Ketoconazole (keto) is drug used in prostate cancer to block the release of testosterone from the adrenal glands, typically administered in conjunction with steroids to avoid side effects.
- 5/30/2012 Working Through Sexual Dysfunction after Prostate Cancer | "Working through" is a good description of a man’s journey with sex after prostate cancer treatment.
- 5/24/2012 USPSTF Panel Announces Final Recommendation Against PSA Screening for Prostate Cancer | The task force discouraged the use of the test by issuing it a Grade D rating.
- 5/23/2012 Role of Fusion Gene Holds Promise of Therapy for Cancers, Including Prostate | Prostate Cancer Foundation funded research has shown that 50 percent of all prostate cancers carry the TMPRSS2-ERG gene fusion, an abnormal juxtaposition of TMPRSS2 and ERG genes.
- 5/21/2012 Molecular Subtype of Prostate Cancer Validated with Funding from PCF | Defect in SPOP gene found in up to 15 percent of all prostate tumors, aggressiveness yet to be determined
- 5/17/2012 Dendreon’s Provenge Works Best for Patients With Low PSA, Scientists Say | The study wasn’t designed to get a statistically significant answer to this question, meaning the finding could be a fluke.
- 5/15/2012 Benefits of Zytiga Out Rule Cost Concerns, Drug Approved In United Kingdom | The decision came after NICE ruled against Zytiga eight months ago, stating that its benefits didn’t justify its cost.
- 5/15/2012 U-M School of Dentistry Researchers Discover Possible Link between One Form of Chemotherapy and Bone | Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry is the second U-M School of Dentistry researcher to deliver new data relating to prostate cancer and metastases to the bone.
- 5/15/2012 DNA Biomarker Discovery Focuses on DNA Methylation | Published in Clinical Cancer Research today, Krishna Donkena, PhD and her research team at the Mayo Clinic found that DNA biomarkers produced by DNA methylation may be used to better detect prostate cancer recurrence and metastases.
- 5/10/2012 In the Middle and on the Sideline: The Experience of Spouses of Men with Prostate Cancer | In a study conducted by the Department of Health and Care Sciences, University of Tromse, Norway and Mid Sweden University, researchers found that spouses play an important role in how well patients with prostate cancer manage their illness.
- 5/10/2012 1 of 6 Cancer Deaths Worldwide Caused by Preventable Infections | Cervical cancers account for about half of the infection-related cancers in women, while liver and gastric cancers account for about 80% of those in men
- 5/10/2012 Analysis of Genetic Abnormalities in Prostate Tumors and Surrounding Benign Tissue Might Predict Cancer Progression and Recurrence |
- 5/8/2012 Prostate Cancer Screening Benefits Younger, At-Risk Men | Screening younger men and men at risk of prostate cancer is beneficial and should not be abandoned, according to researchers who conducted a large new study in Europe.
- 5/7/2012 New Device to Capture and Characterize Prostate Cancer Patients’ Circulating Tumor Cells for Disease | Circulating tumor cells, found in patients’ bloodstreams, are shed from tumors and may be responsible for metastases.
- 5/7/2012 Urine Test Shows Promise in Reducing Prostate Cancer Biopsies | Pre-biopsy urine screen improves both disease detection and high-grade tumors prediction
- 5/7/2012 Harnessing the Body's Immune System to Fight Prostate and Other Cancers | Since the 1990s, the Prostate Cancer Foundation understood the potential immunotherapy research could hold for many types of cancers.
- 5/7/2012 Scientists Identify Therapy-Resistant Subset of Tumor-Propagating Prostate Cancer Cells | The resistance of prostate cancer (PCa) to androgen deprivation therapy (ADT) and chemotherapy may be due to a subset of cancer cells characterized by low levels of prostate specific androgen (PSA) expression, scientists claim.
- 4/30/2012 Vitamin D Levels Linked to Survivorship of Prostate Cancer—Genetic Variations May Play Crucial Role | A study that looked at the association between blood levels of vitamin D and prostate cancer has found that men with the highest levels of the vitamin were 57% less likely to develop a lethal form of the disease.
- 4/27/2012 Robotic Surgery Dominant in Prostate Cancer | Fueled in part by fewer complications, robotic-assisted radical prostatectomy (RARP) has surpassed open surgery as the predominant surgical approach to localized prostate cancer, analysis of a national database showed.
- 4/23/2012 PCF-Funded Young Investigator, Dr. Tarek Bismar, Awarded Donald Coffey Prize for the Best Research Paper by BJUI | PCF-funded Young Investigator, Dr. Tarek Bismar, was awarded the Donald Coffey Prize for the best research paper of 2011, titled "PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer."
- 4/17/2012 Proton Therapy Update: No Evidence That Benefits Justify Cost | Dr. Matthew Cooperberg suggested that IMRT was associated with better results in the article, though it did cause more erectile dysfunction than 3D conformal radiation.
- 4/17/2012 HIFU Technology Progresses, More Clinical Research Is Needed | A recent study conducted at the University College London shows that HIFU may offer the promise of effective ablation in low-grade lesions, if all cancer cells can be reached.
- 4/10/2012 Bone Microenvironment Important in Approaching and Treating Prostate Cancer | Evan Keller, DVM, PhD, a Prostate Cancer Foundation funded researcher at the University of Michigan, found that targeting the bone microenvironment may help guide treatment approaches for prostate cancer patients.
- 4/10/2012 Two New Prostate Cancer Genes Show Increased Risk of Disease Diagnosis | Two inherited genetic variations that may help identify a man’s risk of being diagnosed with aggressive prostate cancer
- 4/9/2012 Prostate and Breast Cancer Vaccine Progressing | The progress of vaccines continue to progress and PCF is pleased to see a growing interest in the field.
- 4/5/2012 PCF Researcher Dr. Carl June Presents Results on "Performance Enhanced" T-Cell Therapy in Leukemia | Dr. June described a therapeutic method that successfully used a patient’s own lymphocytes to treat a type of leukemia.
- 4/5/2012 Dr. Karen Knudsen Identifies "Next Generation" Gene Targets for Prostate Cancer | Karen Knudsen, PhD participated in a session at the AACR conference focused on identifying the next generation of gene targets for prostate cancer.
- 4/5/2012 PCF Scientific Advisory Board Member Martin G. Pomper Speaks on Molecular Imagining and Theranostics | Dr. Martin G. Pomper, reported on the increased need for studies of the genetic and molecular basis of cancer, including the use of molecular imaging for the use of noninvasive analysis of cancer biology in vivo.
- 4/4/2012Dr. Charles Sawyers Discusses the Coming of Age in Pathway-Targeted Therapeutics, MDV3100 | During a plenary session at the AACR conference, panel speakers discussed therapies targeting oncogenic signaling pathways and their continued maturity within the field of cancer research.
- 4/4/2012 Data Presented by Dr. Sarah Nechuta on the Role of Cruciferous Vegetables and Sulphorophane in Broccoli | Over the past 19 years, PCF funding has stimulated some of the most rigorous nutrition and diet research of any cancer research funding agency.
- 4/4/2012 Correlation Between Excess Body Weight and Prostate Cancer Identified by Dr. Vincent Freeman | Endpoint results showed that the risk for cancer recurrence increased with increasing BMI
- 4/4/2012 First Prostate Nanomedicine Shows Positive Results in Phase I Trials | This research represents the first time a nanomedicine has moved from the test tube to the clinic to target prostate cancer cells effectively and to deliver docetaxel in high concentrations safely.
- 4/4/2012 PCF-Supported Researcher Dr. Charles Ryan Focuses on New Prostate Cancer Drugs | Dr. Charles Ryan presented data results on agents used in the treatment of prostate and genitourinary cancers at the 103rd annual AACR conference.
- 4/3/2012 PCF-Funded Investigator Presents on Investigational Drug Galeterone | Galeterone showed great than 30% PSA reduction in all patients with some patients demonstrating 90% PSA declines.
- 4/3/2012 Dr. Gulley, PCF-Supported Scientist, Discusses Differences in Targeted and Immune Therapies | PCF-supported researcher Dr. James Gulley presented data results during the plenary session at the AACR conference today.
- 4/3/2012 PCF-Funded Young Investigator Presents Research on Imaging Androgen Receptor Signaling | Dr. Ulmert and his research teams’ work are focused on the development of radiotracers to detect cancers or monitor treatment responses, with specific attention to clearer usage in the clinic.
- 4/3/2012 Bringing Next-Generation Sequencing to the Cancer Clinic for Precision Medicine | Recent advances in next generation sequencing afford new opportunities to uncover specific genetic mutations that drive cancers.
- 4/2/2012 PCF-Funded Researcher Presents Data on Chromatin States Found In Stem Cells | Dr. De Marzo at Johns Hopkins Department of Pathology and graduate student colleague Laxmi Pellakuru presented a poster session focused on understanding how molecular mechanisms are responsible for altering chromatin states in stem cells and cancer cells.
- 4/2/2012 PCF Partner Institutions Honored at AACR Opening Ceremony | The opening ceremony at the American Association of Cancer Research (AACR) conference awarded two PCF-supported institutions, the Institute of Cancer Research (ICR) and the Royal Marsden Hospital, with the AACR Team Science Award.
- 4/2/2012 PCF Award Recipient Steven Balk Chairs Session on Advances in Androgen Receptor Discovery | Prostate Cancer Foundation Challenge Award recipient, Steven P. Balk at Beth Israel Deaconess Medical Center in Boston, MA chaired a session focused on recent advances made in targeting androgen receptors for prostate cancer prevention and therapy.
- 4/1/2012 PCF-Funded Scientists Say Diabetes Medication Shows Promise Against Cancers, Including Prostate | Data presented at the annual AACR meeting on metformin showed promising results against a variety of different cancers, including prostate cancer.
- 4/1/2012 Robotic High-Throughput Screen Featured at AACR | William Sellers, Vice President of Oncology at Novartis Institutes of Biomedical Research, featured the development of a robotic high-throughput screen that allows testing 1,300 drugs on 70 different cancer cell lines, while at the same time, generates 27 million data points.
- 4/1/2012 PCF Support Facilitates AACR Recognition Awards | During the American Association for Cancer Research (AACR) annual meeting, titled "Accelerating Science: Concept to Clinic," three Prostate Cancer Foundation supported researchers were recognized for their early-career efforts in the field of prostate cancer research.
- 3/23/2012 Dr. Ballentine Carter Elected Trustee of the American Board of Urology | Dr. Ballentine Carter, a Prostate Cancer Foundation (PCF) funded researcher, mentor and sterling clinician, was elected Trustee of the American Board of Urology (ABU), beginning his six-year term on February 28, 2012.
- 3/29/2012 CD47 Protein Is an Actionable Target in Multiple Cancers | Reported by Time, a working group of scientists at Stanford University School of Medicine, led by professor of pathology Irving Weissman, successfully tested an antibody treatment that blocks the protein CD47
- 3/23/2012 Dr. Charles Sawyers Elected AACR President | Dr. Charles Sawyers, Prostate Cancer Foundation funded researcher since 1996, supporter and long-time friend, was named president-elect of the American Association for Cancer Research (AACR) and will begin his term in April 2013.
- 3/22/2012 Scientists Identify New Mechanism of Prostate Cancer Cell Metabolism | Study results are published in Cancer Discovery, a journal of the American Association for Cancer Research.
- 3/21/2012 Cadmium Studied in Prostate Cancer at Marshall University | A report from Marshall University found preliminary data on cadmium, a toxic metal found in industrial workplaces, and it’s possible role as a key driver in the development of prostate cancer.
- 3/20/2012 One Size Does Not Fit All for Prostate Cancer Treatment | A recent study in the Achieves of Internal Medicine found that during the past decade, some men with low-grade prostate cancer may have been treated with therapies that are too aggressive.
- 3/20/2012 Spotlight on Prostate Cancer – Lower Incidence Rates in Asia? | Prostate cancer incidence rates in Malaysia have been reported as one of the lowest in the world, as shared in The Sun Daily today.
- 3/20/2012 Prostate Cancer Risk Could Increase With Use of Hair Loss Drug: Health Canada | Health Canada | High-grade prostate cancer is an aggressive type of prostate cancer
- 3/15/2012 Extended European Study Shows 11-Year Results: PSA Screening Reduces Prostate Cancer Deaths by 21%, But Not Overall Deaths | While the debate over the value of PSA screening continues, European researchers have released data from two additional years of follow up in the European Randomized Study of Screening for Prostate Cancer.
- 3/14/2012 Dr. Patrick Walsh, Renowned Prostate Cancer Researcher, Receives the Amory Prize | Patrick Walsh, MD, of Johns Hopkins University School of Medicine, today received the prestigious Amory Prize award from the American Academy of Arts and Sciences.
- 3/14/2012 Circumcision May Lower Prostate Cancer Risk | Over One Quarter of All Cancers Are Caused By Infection
- 3/12/2012 PCF Initiates China Research Program | The Prostate Cancer Foundation (PCF) launched a new research initiative in China, partnering with the Chinese Urological Association, in an effort to promote and fund prostate cancer research.
- 3/9/2012 Novel Therapy Zytiga Approved by FDA for Metastatic Prostate Cancer | Zytiga® (abiraterone acetate) was approved by the US Food and Drug Administration in April 2011 for the treatment of metastatic castration-resistant prostate cancer (mCRPC), following docetaxel chemotherapy.
- 3/9/2012 PCF Announces Winners of Young Investigator Award in China | The Prostate Cancer Foundation announced its first two Young Investigators in China to launch its initiative to identify, fund and promote innovative research projects within China.
- 3/8/2012 China on Front Lines of Fight Against Prostate Cancer | How does the body of a Chinese farmer differ from that of his African-American counterpart?
- 3/8/2012 No Increased Risk of Cardiovascular Death With Androgen Deprivation Therapy for Prostate Cancer | New results from a meta-analysis show no apparent association between androgen deprivation therapy (ADT) and cardiovascular events and death in men with prostate cancer.
- 3/8/2012 FDA Approved Treatment Used for Novel Application | Zytiga (abiraterone acetate) was approved by the Food and Drug Administration in early 2011 for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy.
- 3/7/2012 PCF Chairman Michael Milken Joins Focused Ultrasound Foundation Council | The Focused Ultrasound Foundation announced today that medical research activist, philanthropist and financier Michael Milken has joined its Council, a select group of advisors and advocates who are helping to advance the organization's mission.
- 3/7/2012 Local Doctors to Use Gene Tests In Prostate Cancer Treatment With PCF Support | The Prostate Cancer Foundation in China (PCF China) is an important step forward in expanding our global research network and knowledge exchange.
- 3/2/2012 PSA Debates Continue Across the Globe, Australia Weighs In | Contradictory studies continue throughout the globe regarding the long-term survival value of PSA blood testing for prostate cancer.
- 3/1/2012 Nymox Announces U.S. Phase 2 Clinical Trial of NX-1207 for New Indication-Prostate Cancer | Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the initiation of a Phase 2 U.S. clinical trial to evaluate the company's NX-1207 drug for the treatment of low grade localized prostate cancer.
- 2/29/2012 Researchers Work is Parallel to PCF-Funded Investigator | PCF funding has stimulated some of the most rigorous nutrition and diet research of any cancer research funding agency during the past nearly 20 years.
- 2/27/2012 High-Grade Prostate Cancer Linked to Metabolic Syndrome | Metabolic syndrome does not increase men's risk of prostate cancer (PCa) overall
- 2/27/2012 Initial Funding for Cancer Vaccine Leads to Further Progress | Since the early 1990’s, the Prostate Cancer Foundation has funded early research on immunotherapies and their role in prostate cancer.
- 2/27/2012 Cancer Discovery Shows Promise of New Drugs | Researchers at the University of California, San Francisco discovered how a protein can go awry, leading to prostate cancer metastasis.
- 2/27/2012 A Driver of Prostate Cancer Progression Identified by Two PCF-Funded Researchers | The article below was funded by two PCF Competitive Awards (valued at $100,000 each)
- 2/24/2012 Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data | Active Biotech's (NASDAQ OMX NORDIC: ACTI) and Ipsen's castrate resistant prostate cancer project, TASQ will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.
- 2/24/2012 Myriad's Prolaris Test Shown to Significantly Predict Prostate Cancer Outcome in Needle Biopsy Tissue | Myriad Genetics, Inc. announced today that a study published in the British Journal of Cancer demonstrated the prognostic ability of the Company's Prolaris test in needle biopsy material.
- 2/16/2012 Some Men Die From Other Causes Outside of Initially Diagnosed Prostate Cancer | Researchers found that some men with prostate cancer have an increased risk
- 2/15/2012 PCF-Funded Discovery Results in a New Diagnostic Test to Diagnose Prostate Cancer | The US Food and Drug Administration (FDA) approved today a urine-based molecular diagnostic test that aids clinical decision-making for repeat prostate biopsies in men who have had a previous negative biopsy.
- 2/13/2012 Nerve Sparing Study Plays Important Role in Sexual Function | The vast majority of men who have a prostate cancer operation can retain their ability to orgasm if the surgery is carried out without removing the nerves that surround the prostate gland like a hammock, according to a study in the February issue of the urology journal BJUI.
- 2/10/2012 Mentorship and Data Exchange Expand Prostate Cancer Research | Researchers at Thomas Jefferson University are investigating the role of curcumin (a spice originating in India) and its role in slowing prostate cancer tumor growth.
- 2/9/2012 Heart Disease May Be a Risk Factor for Prostate Cancer | In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.
- 2/9/2012 Brachytherapy Can Be Successful for High-Risk Prostate Cases, Too | Although brachytherapy has not been considered a highly effective form of treatment for high-risk prostate cancer, it was shown to reduce prostate cancer–specific mortality (PCSM) compared with external beam radiation therapy (EBRT) alone in a recent large analysis.
- 2/8/2012 ProstaCaid™ Inhibits Tumor Growth in a Xenograft Model of Human Prostate Cancer [JOURNAL] | We have recently demonstrated that the dietary supplement ProstaCaid™ (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro.
- 2/8/2012 Third Peer-Reviewed Study Proves Botanical Formula Fights Prostate Cancer Without Toxicity | Scientists at Indiana University, Methodist Research Institute, study a botanical formula that kills aggressive prostate cancer tumors.
- 2/7/2012 CTC Technology Detects Presence of Cancer and Serves as a Less Invasive Diagnostic Tool | Through direct research funding and data sharing, the Prostate Cancer Foundation funding has advanced the field of Circulating Tumor Cell (CTC) technology, which may soon deliver new gold standards for prostate cancer diagnostics and biomarkers.
- 2/7/2012 Urine Test Could Supplement Prostate Cancer Biopsy | PCF funding continues to advance early diagnostics
- 2/7/2012 Fast Track Treatment Continues to Make Progress | On June 6, 2011, the Prostate Cancer Foundation reported promising Phase III clinical trial results for Radium-223 (Alpharadin) that were presented at the annual American Society of Clinical Oncology meeting in Chicago.
- 2/7/2012 Study Analyzes Side Effects, Costs of Prostate Cancer Treatment | Nearly a quarter of a million men are diagnosed with prostate cancer each year, and while survival rates are increasing, toxicity of treatments has not been well studied over a long period of time.
- 2/7/2012 Debating How and How Often to Test for Prostate Cancer [AUDIO] | African American men -- and others with a higher-than-usual risk for prostate cancer -- are at the middle of a debate about whether the main screening tool for the disease is any good at all.
- 2/7/2012 Abbreviated Radiotherapy Shows Promise in Prostate Cancer | Dramatically condensing radiation treatment for early prostate cancer into just five fractions produces good results without much toxicity, an early-phase study suggested.
- 2/2/2011 OGX-427 Used with Prednisone Shows Promising Results for Prostate Cancer Patients | A panel of PCF-Safeway funded Canadian and U.S. researchers presented data from a Phase II clinical trial using OGX-427 in combination with prednisone versus prednisone alone at the 2012 ASCO Genitourinary meeting this week in San Francisco.
- 2/2/2012 Promising New Therapeutic Targets Bone and Disperses Radiation | Alpharadin may decreases bone metastases and reduce death
- 2/2/2012 Seed Therapy for Prostate Cancer May Zap Fertility | Radioactive "seeds" that are sometimes used to treat early prostate cancer may do widespread damage to the DNA in a man's sperm, a small study finds.
- 2/1/2012WSJ Article Shows Rapid Progress in Prostate Cancer | Research and treatment advances continue to climb
- 2/1/2012 Researchers’ Work in Prostate Cancer and Exercise Advances | June Chan focuses on early-stage disease
- 1/31/2012 Cooked Tomatoes Slow Cancer Growth And Even Kill Prostate Cancer Cells Say Researchers |
- 1/31/2012 Ronald Yap Designs an App to Track Prostate Health | Prostate Pal and Bladder Pal are mobile apps designed to help people track their prostate and bladder health along with their health care provider.
- 1/31/2012 PCF-Funding Leads to New Bone Scale Index to Measure Remissions in Bone Metastases | Important Tool for Physicians to Use on Patients
- 1/30/2012 Brown Fat Plays Important Role in Weight Management, Prostate Cancer | PCF-funded investigator explores its role
- 1/27/2012 PCF Lays the Foundation for Roswell Park Vaccine Trial | Prostate Cancer Foundation funding to Drs. Jim Allison and Padmanee Sharma (who studied NY-ESO-1 and other tumor antigens for chemotherapy) provided a foundation for a research breakthrough made at Roswell Park Cancer Center.
- 1/24/2012 Drug May Slow Early Prostate Cancer: Study | Typically used for an enlarged prostate, it could prevent need for aggressive treatment
- 1/23/2012 Androgen Receptor Pathway Agents Continuing to Change the Landscape of Prostate Cancer | For men diagnosed with prostate cancer, treatment options of many forms are readily available for use.
- 1/17/2012 New Jersey Leads the Nation in Opposing USPSTF PSA Testing Recommendation | Governor Chris Christie Signs Resolution Passed Unanimously by Legislature
- 1/12/2012 Major Prostate Cancer Gene Mutation Identified | Family history and early diagnosis vital in understanding risk
- 1/11/2012 A Model For Life Sciences Research Funding | Ever wonder where the money goes when you donate to a large “Fight This Cancer” campaign?
- 1/5/2012 Energy and Advocacy Preserve Crucial PCa Research Funds | With efforts from the Prostate Cancer Foundation and the U.S. prostate cancer advocacy community, led by the Prostate Cancer Roundtable, the 2012 budget for Congressionally Directed Medical Research Programs was preserved.
- 1/4/2012 Cancer Incidence, Death Rates Continue to Drop: Report | One million lives saved, largely because of improved prevention, detection and treatment
- 12/20/2011 Making Sense of Cancer Screening Updates | It's important to discuss testing schedule with your doctor
- 12/20/2011 Do Statins Increase Your Risk of Prostate Cancer? | Two research professionals weigh in on the controversial topic
- 12/12/2011 Are Too Many Older People Screened for Cancer? | Debate over testing should weigh health and life expectancy, expert says
- 11/15/2011 Could Women's Use of 'the Pill' Raise Men's Prostate Cancer Risk? | New finding is highly speculative and doesn't demonstrate cause-and-effect, expert says
- 11/3/2011 PCF Funding Leads to MDV3100 Clinical Successes | All trial participants receive drug, not placebo
- 11/2/2011 Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer | But, surgery might even improve survival more, expert says
- 11/1/2011 Dr. Oliver Sartor on Radium-223 at 2011 PCF Scientific Retreat | Dr. Oliver Sartor, a member of the PCF Research Community, was the principal investigator for the study sites in the United States.
- 11/1/2011 What to Make of the Big Prostate Cancer News | Dr. Mehmet Oz and Dr. Mike Roizenoff offer sensible advice on the PSA Test and Vitamin E.
- 11/1/2011 AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy | PCF-funded researchers partner with AgonOx Partners and MedImmune to develop tumor-specific agonist
- 10/19/2011 Death by Bureaucracy | Newt Gingrich discusses the USPSTF and their recommendation regarding PSA Testing
- 10/11/2011 Extra Vitamin E May Be Associated With Prostate Cancer | Increase in risk is small, but finding suggests that supplement use can be harmful, researchers say
- 10/10/2011 PCF Responds to U.S. Protective Services Task Force Recommendation on PSA Screening | While needing better guidelines, the PSA still plays an important role in detecting early prostate cancer in informed patients
- 10/7/2011 U.S. Preventive Services Task Force Issues New Recommendation on PSA | PCF to Issue Response on October 10, 2011
- 9/29/2011 Otherwise Healthy Older Men Undertreated for Prostate Cancer| Yet younger men with other serious health issues may be overtreated for the cancer, research shows
- 9/27/2011 U.S. Scientists Map Genome of Advanced Prostate Cancer | Researchers discover genetic 'hypermutations' that help tumors resist common therapies
- 9/26/2011 Couples Counseling Boosts Sex Lives After Prostate Cancer | Both face-to-face and Internet counseling improved erectile dysfunction, love lives, study found
- 9/22/2011 In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization| Experts stress procedure is not benign, strong antibiotics should be given beforehand
- 9/20/2011 New Test Predicts Risk for Impotence After Prostate Cancer Therapy | Series of questions given prior to treatment could help men decide on type of care, researchers say
- 9/19/2011 FDA Expands Approval for Denosumab | On Friday, September 16, 2011, the Food and Drug Administration (FDA) approved denosumab (Prolia) to increase bone mass in non-metastatic prostate cancer patients undergoing androgen deprivation therapy (ADT).
- 9/7/2011 Abiraterone (Zytiga) Approved in European Union | Today’s approval of Abiraterone (Zytiga) in the European Union (EU) offers a new treatment option for more than 70,000 patients living with prostate cancer in European member states.
- 8/23/2011 FDA to Decide by April 26 on New Xgeva Application | Prevention of metastases represents promising new use for Xgeva
- 8/23/2011 FDA Grants Fast Track Designation to Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone | Decision may make new treatment available for patients faster
- 8/22/2011 5-Gene Signature Identifies Lethal Varieties of Prostate Cancer and May Better Direct Patients to Appropriate Levels of Treatment | Discovery enabled by collaborative effort of scientists at more than a dozen institutes in U.S. and Sweden
- 8/12/2011 Many Men Underestimate Prostate Surgery Side Effects | Incontinence, impotence often worse than anticipated, study finds
- 8/3/2011 New Urine Test Provides Greater Clarity in Diagnosing Prostate Cancer | Detecting Two Cancer-Specific Genetic Fingerprints Can Better Direct Patients and Eliminate Unnecessary Prostate Biopsies
- 7/29/2011 UT Southwestern PCF Young Investigator Identifies New Pathway Explaining Resistance to Prostate Cancer Treatment | Discovery Opens Door to New Target for Drug Development
- 7/28/2011 Abiraterone (Zytiga) Approved in Canada | Janssen Inc. announced today that after a priority review, Health Canada has approved ZYTIGA™ (abiraterone acetate), the oral medication for the treatment of men with metastatic prostate cancer.
- 7/27/2011 Intermittent Androgen Deprivation | Changing the standard of care for men with recurrent prostate cancer
- 7/25/2011 Final European Approval of Abiraterone (Zytiga) Expected Within Weeks | Approval will open new treatment option for more than 70,000 patients each year in the EU
- 7/13/2011 For Some Prostate Cancer Patients, Combo Treatment Improves Survival | For men at 'intermediate risk,' radiation plus 4 months of hormone therapy improves survival, study finds
- 7/6/2011 Stearns' Amendment to Increase Prostate Cancer Research under Department of Defense Gets Bipartisan Approval | $16 Million Increase in Prostate Cancer Research Adopted by Voice Vote
- 6/30/2011Medicare to Cover Cost of Provenge | The decision today by the Centers for Medicare & Medicaid Services (CMS) to immediately start covering Provenge is good news for many prostate cancer patients with advanced metastatic disease.
- 6/27/2011 Duke Team Finds New Clues to How Cancer Spreads | PCF-funded investigator lead author of the study
- 6/21/2011 Smoking, Prostate Cancer a Deadly Mix | But risk drops for men who have given up tobacco for 10 years, study finds
- 6/9/2011 Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer | Calling for warning labels, FDA says meds shouldn't be given until other urological conditions are ruled out
- 6/6/2011 News from ASCO: Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients | Good news for patients with castration-resistant prostate cancer that has spread to the bone
- 6/6/2011 Jury Still Out on Radiation for Early Prostate Cancer | There's too little evidence to say it's superior to 'watchful waiting,' study says
- 5/30/2011 Medicare Moves to Pay for Prostate Cancer Drug Provenge | This is encouraging news for many prostate cancer patients with advanced metastatic disease who may benefit from treatment with Provenge.
- 5/23/2011 Regular Brisk Walks May Protect Prostate Cancer Patients | Study found those who took them lowered chances of disease progression, death
- 5/23/2011 Half of Prostate Cancers Could Potentially Benefit From New Type of Cancer Drugs | Work was a team effort led by PCF-funded investigator Dr. Arul Chinnaiyan
- 5/18/2011 Earlier PSA Test Best Predicts Risk of Dying From Prostate Cancer | This may cut down on unnecessary screening, researchers say
- 5/17/2011 Could Coffee Lower Men's Risk for Prostate Cancer? | In study, drinking 6 or more cups per day was linked to reduced odds for aggressive disease, but more research needed
- 5/17/2011 Surgery Viable for Advanced Prostate Cancer, Study Finds | After removal of their prostate gland, 80% of patients survived 20 years
- 5/16/2011 Smoking Might Raise Odds for Prostate Cancer's Return | Study found that smokers had steeper rise in blood PSA levels, a harbinger of recurrence
- 5/16/2011 PSA Test Could Be Improved to Spot Prostate Cancer | Preliminary studies point to ways to have the screening benefit more men
- 5/16/2011 Prostate Cancer Survival May Be Especially Tough on Gay Men | Post-treatment quality of life scores worse than for heterosexuals, study finds
- 5/4/2011 Aggressive Treatment May Be Beneficial for Early Prostate Cancer | In men under 65, death risk was lower than for those who chose watchful waiting
- 4/28/2011 FDA Aproves Zytiga (abiraterone acetate) for Late-Stage Prostate Cancer | The Prostate Cancer Foundation (PCF) applauds the approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy.
- 4/19/2011 KRAS Gene Fusion in Prostate Cancer | This recently published study suggests that rare gene fusions or rearrangements of a gene called KRAS, may be associated with more aggressive metastatic prostate cancers and tumor progression.
- 4/1/2011 Prostate Cancer Screening Doesn't Cut Death Rates | A 20-year study from Sweden suggests that screening for prostate cancer does not substantially reduce the risk of death from the disease.
- 3/28/2011 Short Course of Hormone Therapy Boosts Prostate Cancer Survival | Coupled with radiation, six months of treatment improved odds in locally advanced cases, researchers found
- 3/25/2011 FDA Approves Drug Found to Prolong Lives of Melanoma Patients | Today’s FDA approval of ipilimumab for the treatment of malignant melanoma is the second immunotherapy approved for the treatment of cancer.
- 3/24/2011 Prostate Cancer Spreads to Bones by Overtaking the Home of Blood Stem Cells | Like bad neighbors who decide to go wreck another community, prostate and breast cancer usually recur in the bone, according to a new University of Michigan study.
- 3/7/2011 UCLA Researchers Use 'Nano-Velcro' Technology to Improve Capture of Circulating Cancer Cells | New method may help improve diagnosis and treatment-monitoring of cancer
- 3/2/2011 Scientists Target Aggressive Prostate Cancer | SPINK1 gene could be to prostate cancer what HER2 has become for breast cancer
- 2/27/2011 PSA Screening for Prostate Cancer Dips in Large U.S. Health Network | Follows 2008 guidelines reporting that aggressive PSA screening had led to harm from unnecessary treatment
- 2/27/2011 Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer | Measuring changes over time leads to unnecessary biopsies, researchers say
- 2/23/2011 Newer Drug May Help Prevent Fracture in Men With Prostate Cancer | Slightly fewer patients on denosumab experienced 'skeletal events' than those on Zometa, study found
- 2/15/2011 PSA Test Cut-off Could Signal Low-Risk Prostate Cancer | Another study suggests drug for enlarged prostate might also curb tumor progression
- 2/15/2011 New Gene Test May Identify Aggressive Prostate Cancers | Prostate Cancer Foundation (PCF) funded researcher Dr. Ronald DePinho at the Dana-Farber Cancer Institute in Massachusetts reported a new test that may classify aggressive cancers better than Gleason Grade scoring.
- 2/15/2011 Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? | Researchers say these men may turn out to be candidates for screening, but more study needed
- 2/9/2011 First Look at Prostate Cancer Genome Yields Insights | Newly detected DNA changes may eventually lead to better treatments
- 1/05/2011 Exercise May Improve Odds Against Prostate Cancer Death | This week’s announcement of a Veridex (a Johnson & Johnson company) five-year, $30 million partnership with researchers at Massachusetts General Hospital
- 1/4/2011 PCF $3 Million Investment in Circulating Tumor Cells Delivers Ten‐Fold Investment by Johnson & Johnson within Three Years | Circulating tumor cells (CTCs), found in patients’ bloodstreams, are shed from tumors and may be responsible for metastases.
- 12/3/2010 Scientists Find Protein That May Help Control Prostate Cancer | Discovery could aid in limiting tumor growth and progression, expert says
- 12/1/2010 FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer | Experts were concerned about rare risk of aggressive tumors in patients using the meds
- 11/30/2010 Study Backs 'Active Surveillance' for Low-Risk Prostate Cancer | But the alternative to immediate treatment isn't for all men, researchers say
- 11/17/2010 Medicare Panel Endorses Vaccine for Prostate Cancer Patients | Provenge extends survival by about four months on average and costs $93,000 per individual
- 10/25/2011 PSA Test Reduces Risk of Spread if Prostate Cancer Strikes | Study found screening showed benefit, despite debate about its usefulness
- 10/20/2010 FDA Calls for New Warnings on Some Prostate Cancer Drugs | Hormonal meds linked to slight increase in risk of heart disease, diabetes
- 10/14/2011 Protein Urine Test May Signal Prostate Cancer | Findings could one day be developed into a quick and simple test
- 10/11/2010 Abiraterone Offers Hope in Advanced Prostate Cancer | Drug may reach market next year
- 10/07/2010 Fish-Filled Diet May Cut Prostate Cancer Mortality | Eating fish could reduce risk of dying from the disease
- 9/28/2010 Experimental Test May Spot Prostate Cancer Earlier, More Accurately | Findings are preliminary, and study authors say it could be years before test is available commercially
- 9/27/2010 Surgery a Help for Aggressive Prostate Cancer | Researchers report radical prostatectomy can extend survival rates
- 9/27/2010 Study Backs Prostate Screening for High Risk Men| Men who have a certain genetic variations that put them at higher risk of prostate cancer may benefit from regular screening for the disease, a study by British scientists found Friday.
- 9/25/2010 Exercise May Prevent Prostate Cancer: Study | Report adds to debate over the value of exercise as a protector for men
- 9/17//2010 Uninsured With Prostate Cancer Diagnosed With More Advanced Disease | Patients on Medicaid also more likely to have more severe cases
- 9/16/2010 Sex Problems Vex Men Long After Prostate Surgery | Sexual problems appear to be more distressful to men after prostate-removal surgery than urinary problems do, a new long-term follow-up study shows.
- 9/1/2010 No Risk Seen From Delaying Prostate Cancer Surgery | Patients who delayed surgery by over a year had similar outcomes as those who opted for immediate treatment
- 8/2/2010 Gene Variants in Japanese Prostate Cancer Patients | May be used to screen for susceptibility to the disease in the future
- 7/21/2010 No Link Seen Between Coffee, Prostate Cancer Risk | New research shows no added risk for coffee drinkers
- 7/20/2010 FDA Grants Denosumab Priority Review for Cancer-Related Bone Loss | The FDA has granted denosumab priority review for treatment of bone loss and fractures in patients with advanced prostate cancer.
- 6/17/2010 Cabazitaxel (Jevtana) Approved for Advanced Prostate Cancer | When disease continues to worsen after treatment with standard drug
- 5/4/2010 As FDA Eyes Prostate Cancer Drugs, Experts Urge Caution | Hormonal meds linked to heart risks, but men should not abandon them
- 5/3/2010 FDA Reviews Side Effects From Prostate Cancer Therapy | Doctors urged to consider risks of hormone treatment, inform patients
- 4/29/2010 Prostate Cancer Vaccine Gains FDA Approval | The History of Provenge
- 12/08/2009 Coffee, Exercise Fight Prostate Cancer | Studies show improved survival among men who partake regularly
- 5/21/2009 Vitamin D May Not Protect Against Prostate Cancer | New research from Europe confirms that men's prostate cancer risk has no relationship to how much vitamin D they have in their blood